Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727708 | 0.87 | KIF11 (0.59) | KIF11 | |
| SCHEMBL12694290 | 0.84 | KIF11 (0.72) | KIF11 | |
| SCHEMBL1081184 | 0.84 | KIF11 (0.72) | KIF11 | |
| SCHEMBL8447104 | 0.84 | KIF11 (0.55) | KIF11 | |
| SCHEMBL28634657 | 0.84 | KIF11 (0.55) | KIF11 | |
| SCHEMBL34052 | 0.84 | KIF11 (0.55) | KIF11 | |
| SCHEMBL4531442 | 0.81 | KIF11 (0.52) | KIF11 | |
| SCHEMBL25485591 | 0.79 | KIF11 (0.50) | KIF11 | |
| SCHEMBL4804833 | 0.79 | KIF11 (0.50) | KIF11 | |
| SCHEMBL4530986 | 0.79 | KIF11 (0.50) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583845-A1 | PROGRAMMABLE STIMULI-RESPONSIVE POLYMERIC FORMULATIONS | Ramot at Tel-Aviv University Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| US-12090211-B2 | Methods for preparing antibody drug conjugates | GENENTECH, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-115463152-B | Multifunctional p53 reviving medicine and application thereof | 上海交通大学医学院附属瑞金医院 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024129748-A1 | RNAi AGENT WITH MODIFIED NUCLEOTIDES | ELI LILLY AND COMPANY (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129748-A1 | RNAi AGENT WITH MODIFIED NUCLEOTIDES | ELI LILLY AND COMPANY (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-117700959-A | Hydrolysis-resistant polylactic acid sheet and processing method thereof | 无锡南捷新材料科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2024052920-A1 | PROGRAMMABLE STIMULI-RESPONSIVE POLYMERIC FORMULATIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3438118-B1 | PEPTIDE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-0997466-A1 | Novel antimicrobial lactam-quinolones | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-5656623-A | BACTERICIDES; ANTIBIOTICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-12 | — | — | US | disclosed |
| US-5648346-A | Antimicrobial carbacephem-quinolones | THE PROCTER & GAMBLE COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| US-5646139-A | TREATING AND PREVENTING INFECTION | THE PROCTER & GAMBLE COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5637580-A | ANTIBIOTICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0366189-A2 | Novel antimicrobial lactam-quinolones | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4710568-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1987-12-01 | — | — | US | disclosed |
| US-4642341-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1987-02-10 | — | — | US | disclosed |
| US-4552696-A | GRAMNEGATIVE AND GRAMPOSITIVE BATERIA | BRISTOL-MYERS COMPANY (US) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | KIF11 678/4885 |
| US-12090211-B2 | Methods for preparing antibody drug conjugates | FCGRT, MSN, FCGR3B | KIF11 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.